IQVIA Holdings (IQV) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
IQVIA Holdings (IQV) is supporting a new observational study called “CP382 – Intermittent Catheter (IC) PRO Panel Plan,” led by Coloplast A/S. The study aims to build an electronic patient-reported outcome registry for people who use intermittent catheters as their primary way to empty the bladder, helping companies better track real-world use and patient experience.
The intervention is not a drug or device test but a data-focused effort. It uses an electronic system to collect feedback from catheter users, with the goal of shaping future product design, support programs, and market access strategies.
The study follows an observational cohort design, meaning it will track a group of catheter users at one point in time. There is no random assignment or blinding, and the main purpose is to capture real-world outcomes rather than to test a specific treatment.
The registry is planned to run for up to five years once recruitment starts, giving a long window to gather consistent data. The most recent update was submitted on May 11, 2026, signaling that planning is advanced but participant recruitment has not yet begun.
For investors, this update underscores IQVIA’s role in high-value real-world evidence projects, which can deepen ties with medical device makers like Coloplast. Strong execution could support IQVIA’s data and analytics revenue, while competitors in contract research and health data may respond by expanding their own patient-reported outcome offerings.
The study is not yet recruiting but remains active in setup, with the latest details available on the ClinicalTrials portal.
To learn more about IQV’s potential, visit the IQVIA Holdings drug pipeline page.